15 results about "Abiraterone acetate" patented technology

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.

The application discloses a pharmaceutical composition containing abiraterone acetate and a preparation method and application thereof. An excipient of the pharmaceutical composition contains at least one oil phase, at least one emulsifier and at least one co-emulsifier. The pharmaceutical composition can significantly improve bioavailability and stability of a preparation. The pharmaceutical composition can be further prepared into a capsule.

The invention discloses an abiraterone borane carrying agent with prostatic cancer targeting property as well as a preparation method and application of the abiraterone borane carrying agent. The abiraterone borane compound comprises abiraterone borane and abiraterone acetate borane. According to the embodiment of the invention, based on abiraterone acetate and prostatic cancer targeting and safety of abiraterone, a borane group is introduced into structures of abiraterone acetate and abiraterone acetate, and a novel boron carrying agent is obtained and is used for BNCT treatment of prostatic cancer. The novel boron carrying agent not only retains the CYP17 enzyme inhibitory activity of abiraterone and abiraterone acetate, but also provides the possibility of targeting prostate cancer cells for BNCT by introducing a 10B isotope. Through the innovative medicine design, the curative effect and selectivity of BNCT in prostatic cancer treatment can be remarkably improved, damage to normal tissue is reduced, and a safer and more effective treatment choice is provided for prostatic cancer patients.

1.The name of the design product: poster (abiraterone acetate tablet). 2.The use of the design product: for poster. 3.The design points of the design product: in the combination of shape and pattern. 4.The picture or photo that best indicates the design points: front view. 5.The design product is a flat product, and the rear view, left view, right view, top view and bottom view are omitted.

Methods and compositions are provided for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib, a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present disclosure relates to a pharmaceutical product having at least one batch indication, wherein the pharmaceutical product comprises niraparib and abiraterone acetate.

A drug composition containing abiraterone acetate, and a preparation method therefor and an application thereof. Excipients thereof comprise at least one oil phase, at least one emulsifier, and at least one co-emulsifier. The dug composition can obviously improve the bioavailability and the stability of a preparation. The drug composition can be further prepared as capsules.

The invention relates to the technical field of pharmaceutical preparations, in particular to an abiraterone acetate self-emulsifying soft capsule and a preparation method thereof. The abiraterone acetate self-emulsifying soft capsule comprises a content and a capsule shell, the content is prepared from the following components in percentage by mass: 5 percent to 7.5 percent of abiraterone acetate, 22.5 percent to 48.75 percent of a surfactant, 25 percent to 42.13 percent of a cosurfactant, 10 percent to 30 percent of an oil phase and 0.005 percent to 0.02 percent of an antioxidant; the average particle size of the microemulsion formed by diluting the content with a hydrochloric acid solution with the pH value of 1.2 is 80-100 nm. The abiraterone acetate self-emulsifying soft capsule has good long-term storage stability and high bioavailability, drug absorption is not affected by food intake, and medication compliance of patients can be improved.

The present invention relates to oral suspension dosage form of Abiraterone Acetate. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing dosage form. Moreover, the solubility and stability of the patient compliant Abiraterone Acetate formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides a suspension composition prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible.

This disclosure relates to a combination of abiraterone acetate and niraparib, to free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and to methods of treating prostate cancer with such combinations.

The invention relates to the technical field of drug detection, and discloses a method for detecting beta-lactam compound residues in a drug, which comprises the following steps of: extracting and diluting beta-lactam compounds in the drug through a uniform pretreatment process (adopting 50% acetonitrile) in combination with optimized LC-MS / MS conditions (including specific chromatographic columns, gradient elution procedures and mass spectrum parameters); synchronous quantitative detection of eight beta-lactam compounds (covering cephalosporin and penem) in five raw material medicines (exemestane, etoposide, abiraterone acetate, emtricitinib and cilnimod) with remarkable structural difference is realized, and the limit of quantitation is as low as 0.008 ppm. According to the method, the detection sensitivity is remarkably improved, the trace residue monitoring requirement is met, pretreatment steps are simple and universal, conditions do not need to be adjusted according to different raw material medicines, the detection efficiency and the method applicability are greatly improved, and the problems that the sensitivity is insufficient and the universality is poor in the prior art are effectively solved.